超150个国家参与新冠疫苗全球获取机制

世界卫生组织、Gavi疫苗联盟和流行病预防创新联盟(CEPI)共同推动的COVAX机制已获得全球广泛参与1。75个国家提交意向加入该计划，加上最多90个中低收入国家，共计超过150个国家参与其中，代表全球超过60%的人口1。

COVAX的核心目标是确保新冠疫苗在全球公平分配1。该机制计划到2021年底交付20亿剂经过监管批准或获得世卫组织预认证的疫苗1。疫苗将按人口比例平等分配给参与国家，首先优先覆盖医疗工作者，随后扩大到覆盖各国人口的20%1。

为确保疫苗供应，阿斯利康已承诺为COVAX供应3亿剂新冠疫苗1。COVAX的预付融资工具(AMC)已募集接近6亿美元资金，目标总额为20亿美元1。在疫苗研发方面，CEPI支持的9个候选疫苗中已有7个进入临床试验阶段1。参与国包括阿根廷、巴西、加拿大、日本、韩国、英国等G20成员国及各大洲代表1。

Over 150 countries have joined COVAX, a global mechanism designed to ensure equitable access to COVID-19 vaccines worldwide.1 Seventy-five countries have submitted expressions of interest to participate, alongside up to 90 lower- and middle-income nations, collectively representing more than 60 percent of the global population.1 The initiative is jointly led by Gavi, the Vaccine Alliance (supported by the Gates Foundation), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization.1

The facility aims to deliver 2 billion doses of regulatory-approved or WHO-prequalified COVID-19 vaccines by the end of 2021.1 Participating countries will receive vaccines distributed equally based on population proportions, with initial priority given to healthcare workers before expanding coverage to 20 percent of each nation's population.1 AstraZeneca has committed to supplying 300 million doses to COVAX.1 To support vaccine procurement, COVAX's Advance Market Commitment funding mechanism has raised nearly $600 million toward its $2 billion target.1 Among the nine vaccine candidates supported by CEPI, seven have already entered clinical trials.1 Participant nations span multiple continents and include G20 members such as Argentina, Brazil, Canada, Japan, South Korea, and the United Kingdom.1